Survival depends enormously on why both organs failed, how quickly treatment begins, and whether a transplant is available. When liver failure triggers kidney failure in a hospitalized patient, mortality without transplantation can exceed 90 percent in the most severe forms. With a combined liver-kidney transplant, though, five-year survival reaches the mid-70s. Between those extremes sits a wide range shaped by the underlying cause, the patient’s overall condition, and which therapies can be deployed in time.
Why the Liver and Kidneys Tend to Fail Together
These two organs are deeply interconnected, and failure of one frequently drags the other down. The most well-known pathway runs through the circulatory system. When the liver is severely diseased, high pressure in the portal vein triggers widespread dilation of blood vessels in the abdomen. Vasodilators like nitric oxide flood the system, pulling blood into the gut and away from the central circulation. The body reads this as low blood volume and activates stress hormones that constrict the kidney’s blood supply, starving it of flow even though total blood volume has not actually dropped. Over time, the kidneys shut down not because they are intrinsically damaged, but because they are being strangled by the body’s misguided attempt to compensate for the liver’s failure.
That circulatory cascade is the hallmark of advanced cirrhosis, but other mechanisms matter too. Toxins that the liver would normally clear can accumulate and damage kidney tissue directly. Infections, which are common in liver failure patients because of impaired immune function, can push both organs over the edge simultaneously. In acute scenarios like drug poisoning, the offending substance can injure the liver and kidneys at the same time through independent toxic effects.
Hepatorenal Syndrome and Its Grim Numbers
Hepatorenal syndrome, or HRS, is the condition that develops when severe liver disease causes kidney failure through the circulatory mechanism described above. It comes in two forms. The more dangerous version, historically called type 1 (now termed HRS-AKI), involves a rapid doubling of creatinine or a sharp drop in urine output over days. A European survey found that three-month survival for these patients was roughly 20 percent overall, and among patients with multiple negative prognostic markers, mortality reached 97 percent.
Survival improved for patients who responded to treatment, but response rates have been modest. A large randomized trial published in the New England Journal of Medicine found that the drug terlipressin, given with albumin, reversed HRS in about 32 percent of patients compared to 17 percent on placebo. A more recent U.S. real-world study reported somewhat higher numbers, with an overall response in about 55 percent of patients and full reversal in roughly 31 percent. Responding to terlipressin was linked to lower mortality. Still, even with the best available drug therapy, the majority of HRS patients do not achieve a complete reversal, and without transplantation their prognosis remains poor.
For patients maintained on dialysis while awaiting a liver transplant, the picture is one of extended but difficult survival. One small study found that the average time patients with type 1 HRS survived on hemodialysis was about 236 days, but roughly a third of that time was spent hospitalized. All patients in that series survived their initial hospital stay, yet only one ultimately received a transplant. Dialysis can buy time, but it does not fix the underlying liver disease, and the burden on patients and families is substantial.
How the Cause Shapes Your Odds
The reason both organs failed matters as much as the fact that they did. Some causes carry notably better survival prospects than others.
Acetaminophen Overdose
Acetaminophen (paracetamol) is the most common cause of acute liver failure in many countries, and it can damage the kidneys as well. Kidney injury after an overdose typically appears two to six days after ingestion, following the liver damage that peaks at two to four days. One study of critically ill patients with combined severe liver and kidney injury from acetaminophen poisoning found an overall mortality of 58 percent, though patients who received a liver transplant had a much lower mortality of 20 percent. Among survivors, kidney function recovered within a month in all cases, which is an important distinction: the kidney damage from acetaminophen is usually reversible if the patient survives the acute crisis.
Alcoholic Hepatitis
Acute kidney injury in alcoholic hepatitis is an early and ominous sign. One study found that 90-day mortality was 65 percent in alcoholic hepatitis patients who developed kidney injury, compared to just 7 percent in those whose kidneys were spared. The development of kidney dysfunction was one of the strongest predictors of death, carrying a hazard about eight times higher than in patients without it. Renal dysfunction is common in this population, and its presence consistently signals a worse trajectory.
Chronic Liver Disease With Gradual Kidney Decline
Not all combined liver-kidney failure is acute. Metabolic-associated fatty liver disease and chronic kidney disease share overlapping risk factors, including diabetes, obesity, and insulin resistance. These two conditions frequently coexist, and when they do, they accelerate each other. A large prospective study using the UK Biobank found that fatty liver disease with significant fibrosis was independently associated with higher rates of cardiovascular events and death in patients who also had chronic kidney disease. This slow-burn combination is increasingly common and represents a growing portion of the people who eventually face dual organ failure.
What Predicts Who Survives Without a Transplant
Doctors use several scoring systems to estimate how likely a patient is to survive. The MELD score, which incorporates bilirubin, creatinine, and clotting time, was originally designed to predict short-term mortality in liver disease and is used to prioritize patients on the transplant waiting list. Higher scores mean sicker patients and worse odds. Newer scores like the CLIF-C ACLF score aim to more accurately capture the risk in patients experiencing acute-on-chronic liver failure, where a sudden deterioration piles on top of existing chronic disease.
Beyond formal scores, certain clinical features strongly predict death. Sepsis, hepatic encephalopathy, respiratory failure, and disseminated intravascular coagulation each independently worsen survival when they accompany liver and kidney failure. The more of these complications present simultaneously, the higher the mortality. One prospective study found that mortality correlated strongly with the number of co-morbid conditions, with oliguric patients and those requiring dialysis faring worst.
Newer biomarkers may help identify kidney dysfunction in liver patients earlier. Researchers have found that combining urinary and serum markers can detect hepatorenal syndrome with sensitivity above 90 percent, which could allow earlier intervention before the kidneys deteriorate beyond the point of rescue.
Dialysis and Renal Replacement as a Bridge
When the kidneys fail in a patient with severe liver disease, some form of renal replacement therapy, typically dialysis, becomes necessary. For patients on the liver transplant waiting list, dialysis serves as a bridge to transplant, but the bridge is rickety. In one study of liver transplant candidates who started dialysis, 65 percent died while waiting for a transplant. Only about 31 percent survived to receive a transplant, and 4 percent were discharged without one.
Among patients who did reach transplant, those who had needed dialysis beforehand had substantially worse outcomes. One-year mortality after liver transplant was 30 percent in patients who had been on dialysis before surgery, compared to about 10 percent for liver recipients who had not experienced kidney failure. Three-month post-transplant mortality was similarly elevated, at roughly 16 percent versus 4 percent. The kidney failure does not simply reset once a new liver arrives; it leaves a lasting mark on the body’s ability to recover from major surgery.
For patients not heading toward transplant, dialysis prolongs life but rarely changes the ultimate outcome when the liver remains in failure. One study reported 94 percent mortality among dialysis patients who did not receive a liver.
Artificial Liver Support Devices
Several extracorporeal devices have been developed to take over some of the liver’s detoxification functions, much as dialysis replaces the kidney’s filtering role. The best studied is MARS (Molecular Adsorbent Recirculating System), which uses albumin-based dialysis to remove toxins the failing liver cannot clear.
The evidence on MARS is mixed and depends heavily on the type of liver failure. A meta-analysis found that MARS significantly improved survival in acute liver failure, cutting the relative risk of death by about 39 percent. However, for patients with acute-on-chronic liver failure, where a sudden worsening piles onto pre-existing cirrhosis, MARS did not show a significant survival benefit. A separate systematic review comparing MARS, Prometheus, and another system called Single-Pass Albumin Dialysis against standard medical care found no significant mortality benefit for any of these devices.
A long-term real-world study from a referral center added nuance: while MARS overall did not improve transplant-free survival, patients who received three or more sessions (at least 17 hours of treatment) had dramatically better outcomes than those with shorter courses or no MARS at all. This suggests that the duration and intensity of therapy may matter more than whether the device is used at all, though the finding comes with the usual caveats of retrospective data.
One encouraging result came from a small study using a different approach entirely: standard-volume therapeutic plasma exchange followed by high-dose continuous renal replacement therapy in patients with hepatitis A-related acute liver failure. All patients survived without needing a transplant, with zero ICU, in-hospital, or 28-day mortality. This was a small, specific population, and the results cannot be generalized broadly, but it illustrates that aggressive multimodal support can sometimes rescue patients who would otherwise seem destined for transplant or death.
Combined Liver-Kidney Transplantation
For patients with irreversible failure of both organs, simultaneous liver-kidney transplantation (SLKT) offers the best chance of long-term survival. The numbers are genuinely encouraging compared to the dismal statistics for untreated dual organ failure. A single-center analysis reported cumulative survival rates of 90 percent at three months, 80 percent at one year, and 72 percent at five years. Another center reported similar figures: 93 percent at one year, 80 percent at three years, and 76 percent at five years.
U.S. data from the national transplant registry shows one-year patient survival around 93 percent for simultaneous liver-kidney recipients, with kidney graft survival above 90 percent. These numbers are remarkably good for patients who, without transplant, would have had a very short life expectancy.
A key policy development in the United States has been the “Safety Net” system, implemented in 2017. Before this policy, patients who received a liver transplant alone but whose kidneys did not recover had to compete on the general kidney waiting list like any other candidate. The Safety Net gives these patients priority access to a kidney transplant within a defined window after their liver transplant. Early data suggest this has improved liver graft survival for patients who follow the kidney-after-liver pathway, with one- and three-year liver graft survival jumping from 54 percent before the policy to 86 percent and 81 percent afterward.
The decision of whether to transplant both organs simultaneously or to transplant the liver first and hope the kidneys recover is one of the harder judgment calls in transplant medicine. Transplanting both organs when the kidneys might have recovered on their own wastes a scarce kidney graft. But transplanting only the liver when the kidneys are permanently damaged means the patient may need dialysis again and face a second transplant surgery. Scoring systems help guide this decision, but it remains imperfect.
Children Face a Different Set of Causes
In adults, the most common reasons for combined liver-kidney transplant are cirrhosis with secondary kidney failure. In children, the picture looks quite different. Congenital diseases that affect both organs from birth are a leading indication. Autosomal recessive polycystic kidney disease, which comes with congenital hepatic fibrosis, damages both organs simultaneously. Primary hyperoxaluria type 1 is a liver enzyme deficiency that produces excessive oxalate, which then destroys the kidneys. In these cases, the liver is the source of the problem even though the kidneys bear the brunt of the damage, so transplanting both is not just treating two separate failures but addressing a single underlying disease.
Pediatric survival after combined liver-kidney transplant is roughly comparable to isolated liver transplant in children. Registry data show patient survival of about 87 percent at one year, 82 percent at five years, and 79 percent at ten years. These figures are reassuring for families facing the prospect of dual-organ transplant in a child, though kidney graft survival does decline over the decade, reaching about 67 percent at ten years, which means some children will eventually need a second kidney transplant.
A Worsening Trend
The combined burden of liver cirrhosis and kidney failure has been growing. A nationwide U.S. analysis spanning 1999 to 2023 found that the age-adjusted mortality rate from coexisting liver cirrhosis and kidney failure nearly doubled over that period, rising from 3.6 to 6.3 per 100,000. The trend was relatively flat for the first two decades but accelerated sharply after 2018, with the annual rate of increase reaching nearly 10 percent per year through 2023.
The reasons for this acceleration are not entirely clear from the mortality data alone, but likely contributors include rising rates of alcohol-related liver disease (which surged during and after the COVID-19 pandemic), the growing prevalence of metabolic-associated fatty liver disease, and an aging population with more diabetes and hypertension putting simultaneous stress on both organs. Whatever the causes, the trend means that the question of surviving combined liver and kidney failure is becoming relevant to more people and more families each year.
When the Goal Shifts From Cure to Comfort
Not every patient with liver and kidney failure is a candidate for transplant or aggressive treatment. Age, cancer, active substance use, severe infections, and multiorgan failure beyond just the liver and kidneys can all take transplantation off the table. When that happens, the conversation shifts from survival statistics to quality of remaining life.
Patients with end-stage liver disease who develop kidney failure and are not transplant candidates face a median survival measured in weeks to a few months, depending on the severity of their other complications. Dialysis in this setting can prolong life but often at a significant cost in quality, with frequent hospitalizations and little prospect of meaningful recovery. Some patients and families choose to forgo dialysis in favor of comfort-focused care, a decision that palliative care teams can help navigate. The evidence consistently shows that the number and severity of co-morbid conditions, particularly sepsis and encephalopathy, predict not just whether someone will survive but how burdensome that survival will be.